Results: 2

1.
Figure 1

Figure 1. From: Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

Melanoma phase II study design. Abbreviations: BRAF+, BRAF mutation positive; NRAS+, NRAS mutation positive; PFS, progression-free survival; TMZ, temozolomide.

R E Board, et al. Br J Cancer. 2009 November 17;101(10):1724-1730.
2.
Figure 2

Figure 2. From: Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

The presence of circulating BRAF mutations does not effect progression-free survival. There was no difference in PFS between patients in whom BRAF mutations could be detected in the serum compared with those patients in whom cfDNA BRAF mutations were not detected. HR calculated using an unadjusted Cox proportional hazards model. Abbreviations: BRAF+, BRAF mutation positive; cfDNA, cell-free DNA; HR, hazard ratio; CI, confidence interval.

R E Board, et al. Br J Cancer. 2009 November 17;101(10):1724-1730.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk